Author

Marthe Kirkesæther Brun

Observed names: M K Brun, M.K. Brun, Marthe K. Brun, Marthe Kirkesaether Brun

Observed institutions: University of Nottingham, University of Oslo, King Abdulaziz University, AbbVie (United States), Diakonhjemmet Hospital, Nordic Bioscience (Denmark), Janssen Research & Development (United States), Charité – Universitätsmedizin Berlin

ORCID: 0000-0001-5148-9684

Observed ORCID: 0000-0001-5148-9684

OpenAlex ID: A5025212259

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

2021 · Silje Watterdal Syversen, Kristin Kaasen Jørgensen, et al. · JAMA · 181

PDF

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

2021 · Silje Watterdal Syversen, Guro Løvik Goll, et al. · JAMA · 129

PDF

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

2022 · Johanna Elin Gehin, Guro Løvik Goll, et al. · BioDrugs · 44

PDF

Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

2022 · Marthe Kirkesæther Brun, Guro Løvik Goll, et al. · Journal of Internal Medicine · 43

PDF

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials

2024 · Marthe Kirkesæther Brun, Johanna E Gehin, et al. · The Lancet Rheumatology · 26

Op0017 Therapeutic Drug Monitoring Compared to Standard Treatment of Patients Starting Infliximab Therapy: Results From a Multicentre Randomised Trial of 400 Patients

2020 · S.W. Syversen, G.L. Goll, et al. · Annals of the Rheumatic Diseases · 14

HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases

2023 · Marthe Kirkesæther Brun, Kristin Hammersbøen Bjørlykke, et al. · Journal of Internal Medicine · 11

PDF

Op0060 Clinical Consequences of Infliximab Immunogenicity and the Impact of Therapeutic Drug Monitoring: Secondary Analyses of a Randomised Clinical Trial

2023 · M.K. Brun, K.H. Bjørlykke, et al. · Annals of the Rheumatic Diseases · 4

PDF

OP09 Proactive Therapeutic Drug Monitoring is superior to standard treatment during maintenance therapy with infliximab; results from a 52-week multicentre randomised trial of 450 patients; the NOR-DRUM B study

2022 · K K Jørgensen, S W Syversen, et al. · Journal of Crohn s and Colitis · 4

PDF

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial

2026 · Teresa Holly, Marthe Kirkesaether Brun, et al. · RMD Open · 1

PDF

231: Proactive Therapeutic Drug Monitoring Is Superior to Standard Treatment During Maintenance Therapy With Infliximab; Results From a 52-week Multicentre Randomised Trial of 450 Patients

2022 · Kristin K. Joergensen, Silje W Syversen, et al. · Gastroenterology · 1

P696 Genetic predisposition to infliximab immunogenicity in patients with immune-mediated inflammatory diseases – secondary analyses from a randomised clinical trial

2022 · K Bjørlykke, M K Brun, et al. · Journal of Crohn s and Colitis · 1

POS1077 Cost-effectiveness of proactive terapeutic drug monitoring (TDM) in patients with inflmmatory disease-results from the Nor-Drum trial

2025 · T. Holly, M.K. Brun, et al. · Annals of the Rheumatic Diseases

Abs1163 Personalised Adalimumab Therapy: Development of an Algorithm for Therapeutic Drug Monitoring

2025 · I. Jyssum, J.E. Gehin, et al. · Annals of the Rheumatic Diseases

Pos0007 Hla-dq2 Is Associated With Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases

2022 · M.K. Brun, K.H. Bjørlykke, et al. · Annals of the Rheumatic Diseases

PDF

101: Genetic Predisposition to Infliximab Immunogenicity in Patients With Immune-mediated Inflammatory Diseases – Secondary Analyzes From a Randomized Trial

2022 · Kristin H. Bj⊘rlykke, Marthe K. Brun, et al. · Gastroenterology

Op0301 Risk Factors for Anti-infliximab Antibody Formation: Results From the Randomised Controlled Nor-drum a Trial

2021 · M.K. Brun, G.L. Goll, et al. · Annals of the Rheumatic Diseases

Works count: 17

Citation count: 459

H-index: 7

I10-index: 7